Investigational drug · Phase 3
Birelentinib
Also called: DZD8586
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP).
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
6 still active
All registered trials
6
Any phase or sponsor naming "Birelentinib"
First trial start
2024
Mar 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Birelentinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Diffuse Large B-Cell Lymphoma
- Immune Thrombocytopenia (ITP)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Diffuse Large B Cell Lymphoma
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Birelentinib" as an intervention, largest first.
- Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)Pivotal-lookingNot yet recruiting
Dizal PharmaceuticalsIndustry
NCT07712588 · 880 participants (planned) · Start Sep 2026 · Primary completion Jan 2031
Drug: Birelentinib; Rituximab and 5 more · For: Diffuse Large B-Cell Lymphoma (DLBCL)
Sites: Chongqing, China; Harbin, China; Changsha, China · 5 sites in all
- A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07139873 · 250 participants (planned) · Start Sep 8, 2025 · Primary completion Jan 2029
Drug: DZD8586; Bendamustine and 2 more · For: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sites: Nanjing, China; Tianjin, China
- DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT06539182 · 155 participants (planned) · Start Apr 29, 2024 · Primary completion Sep 2027
Drug: DZD8586; DZD8586 and 1 more · For: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sites: Hefei, China; Beijing, China; Guangzhou, China · 17 sites in all
Dizal PharmaceuticalsIndustry
NCT07154264 · 66 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 2029
Drug: DZD8586; Venetoclax · For: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sites: Hefei, China; Beijing, China; Guangzhou, China · 15 sites in all
Dizal PharmaceuticalsIndustry
NCT07294365 · 60 participants (planned) · Start Jan 15, 2026 · Primary completion Jul 2027
Drug: DZD8586 dose level 1; DZD8586 dose level 2 and 1 more · For: Immune Thrombocytopenia (ITP)
Sites: Jinan, China
Dizal PharmaceuticalsIndustry
NCT07888569 · 26 participants (planned) · Start Oct 23, 2026 · Primary completion Nov 23, 2026
Drug: DZD8586; Rabeprazole · For: Healthy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- TacabrutidegBGB-16673Phase 36 trials
BeOne Medicines (BeiGene) · Chronic Lymphocytic Leukemia, B-cell Malignancy, Small Lymphocytic Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.